2-Chloro-4-dibenzofuran-4-yl-6-phenyl-[1,3,5]triazine | CAS:1472729-25-1

We serve 2-Chloro-4-dibenzofuran-4-yl-6-phenyl-[1,3,5]triazine CAS:1472729-25-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Chloro-4-dibenzofuran-4-yl-6-phenyl-[1,3,5]triazine

Chemical Name:2-Chloro-4-dibenzofuran-4-yl-6-phenyl-[1,3,5]triazine
CAS.NO:1472729-25-1
Synonyms:2-chloro-4-(dibenzo[b,d]furan-4-yl)-6-phenyl-1,3,5-triazine
2-Chloro-4-(4-dibenzofuranyl)-6-phenyl-1,3,5-triazine
4-FPTZ
Molecular Formula:C21H12ClN3O
Molecular Weight:357.79200
 
Specification:r
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 2-Chloro-4-dibenzofuran-4-yl-6-phenyl-[1,3,5]triazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-FPTZ physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-chloro-4-(dibenzo[b,d]furan-4-yl)-6-phenyl-1,3,5-triazine Use and application,2-chloro-4-(dibenzo[b,d]furan-4-yl)-6-phenyl-1,3,5-triazine technical grade,usp/ep/jp grade.


Related News: Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.(2S,5R)-5-(benzyloxyamino)-piperidine-2-carboxylic acid amide manufacturer Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.2-Chloro-5-fluorobenzaldehyde supplier Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.Benzyl 2-Naphthyl Ether vendor Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries.Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries.